Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

详细信息    查看全文

• 作者：Nicholas J. Vogelzang^a ; ^b ; ^{Nicholas.Vogelzang@usoncology.com} ; Karim Fizazi^c ; John M. Burke^a ; ^d ; Ronald De Wit^e ; Joaquim Bellmunt^f ; ^g ; Thomas E. Hutson^h ; Edward Craneⁱ ; William R. Berry^j ; Kevin Doner^k ; John D. Hainsworth^l ; Pawel J. Wiechno^m ; Kejian Liuⁿ ; Michelle F. Waldmanⁿ ; Anita Gandhiⁿ ; Debora Bartonⁿ ; Ulf Jungneliusⁿ ; Abderrahim Fandiⁿ ; Cora N. Sternberg^o ; Daniel P. Petrylak^p
• 关键词：Prostate cancer ; Metastatic castration-resistant prostate cancer ; Circulating tumor cells ; Docetaxel ; Lenalidomide
• 刊名：European Urology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：71
• 期：2
• 页码：168-171
• 全文大小：1038 K
• 卷排序：71

文摘

Elevated circulating tumor cell (CTC) blood levels (≥5 cells/7.5 ml) convey a negative prognosis in metastatic castration-resistant prostate cancer but their prognostic significance in patients receiving chemotherapy is uncertain. The association between CTC counts (at baseline or after treatment), overall survival (OS), and response to docetaxel with lenalidomide was evaluated in a 208-patient subset from the MAINSAIL trial, which compared docetaxel-prednisone-lenalidomide and docetaxel-prednisone-placebo in metastatic castration-resistant prostate cancer patients. Baseline CTCs were < 5 cells/7.5 ml blood in 87 (42%) patients and ≥5 cells/7.5 ml in 121 (58%) patients. Neither tumor response nor prostate-specific antigen response correlated with baseline CTCs. However, CTC count ≥5 cells/7.5 ml was significantly associated with lower OS (hazard ratio: 3.23, p = 0.0028). Increases in CTCs from <5 cells/7.5 ml to ≥5 cells/7.5 ml after three cycles were associated with significantly shorter OS (hazard ratio: 5.24, p = 0.025), whereas CTC reductions from ≥5 cells/7.5 ml to <5 cells/7.5 ml were associated with the best prognosis (p = 0.003).Patient summaryOur study in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy, with or without lenalidomide, showed that patient survival was best predicted by circulating tumor cell count at the start of treatment. A rising circulating tumor cell count after three cycles of therapy predicted poor survival, while a decline predicted good survival.